LIBRETTO-431: Is it time to reconsider randomized phase 3 trials for uncommon oncogenic drivers in non-small-cell lung cancer?

Abstract excerpt

The recently published results of LIBRETTO-4311 pave the way for a new standard of care in the first-line setting for RET-fusion-positive NSCLCs, which raises important clinical questions not only in the therapeutic landscape of advanced NSCLC but also in the drug development process in the era of uncommon molecular subtypes.

Topics

Join the communities discussing this publication.

• Carcinoma, Non-Small-Cell Lung
• Clinical Trials, Phase III as Topic
• RET gene
• Lung Neoplasms
• Mutation
• Proto-Oncogene Proteins c-ret